Literature DB >> 17089038

Clinical significance of insulin receptor substrate-I down-regulation in non-small cell lung cancer.

Chang Hoon Han1, Jae Yong Cho, Jong Tae Moon, Hyung Jung Kim, Se Kyu Kim, Dong Hwan Shin, Joon Chang, Chul Min Ahn, Sung Kyu Kim, Yoon Soo Chang.   

Abstract

Insulin receptor substrate-1 (IRS-1) is an adaptor protein for insulin-like growth factor (IGF) signaling and it is presumed associated with cancer development, progression or clinical outcome of patients harboring solid tumors. Therefore, we investigated by immunohistochemistry, the expression of IRS-1 in the tumor tissues from 94 patients who were diagnosed as stage I non-small cell lung cancer (NSCLC) and had undergone a curative lung resection. The relationships between its intratumoral expression and various clinical parameters were explored. IRS-1 is consistently expressed in the cytoplasm of intrapulmonary bronchial and bronchiolar epithelial cells comprising normal appearing adjacent lung tissues. Forty-one (43.6%) of 94 specimens showed loss of IRS-1 expression. In a subset analysis, IRS-1 was more frequently lost in stage IB than in IA tumors (50.0 vs. 22.7%, p=0.024, chi(2) test), which was reflected by the facts that tumors which showed down-regulation of IRS-1 had larger area than those with IRS-1 expression (18.1 vs. 12.1 cm(2), p=0.044, t-test). Down-regulation of IRS-1 is more frequently observed in squamous cell carcinoma than other cell type lung cancer (p=0.002, chi(2) test) and its expression was not affected by histological grade of differentiation. Comparing pack-years (P.Y.) between groups of smokers whose tumor expressed IRS-1 and those that did not, smokers whose tumor showed loss of IRS-1 expression had higher P.Y. than those whose tumor did express IRS-1 (39.2+/-23.67 vs. 25.6+/-26.61 P.Y., p=0.034, t-test). Intratumoral expression of IRS-1 did not influence disease-free survival, disease-specific survival or overall survival of stage I NSCLC patients, whose median follow-up duration is 7.5 years (95% CI; 7.21-7.86 years). These results suggest that loss of IRS-1 might rather be an early event in NSCLC development than a prognostic factor and that it is more strongly related with squamous cell carcinoma and with smoking.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17089038

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  16 in total

1.  Insulin receptor substrate-1 deficiency drives a proinflammatory phenotype in KRAS mutant lung adenocarcinoma.

Authors:  Heather E Metz; Julia Kargl; Stephanie E Busch; Kyoung-Hee Kim; Brenda F Kurland; Shira R Abberbock; Julie Randolph-Habecker; Sue E Knoblaugh; Jay K Kolls; Morris F White; A McGarry Houghton
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-20       Impact factor: 11.205

2.  Lipocalin 2 deficiency inhibits cell proliferation, autophagy, and mitochondrial biogenesis in mouse embryonic cells.

Authors:  Daozhong Jin; Yuanyuan Zhang; Xiaoli Chen
Journal:  Mol Cell Biochem       Date:  2011-01-14       Impact factor: 3.396

3.  Increased expression of IRS-1 is associated with lymph node metastasis in nasopharyngeal carcinoma.

Authors:  Jiadi Luo; Qiuyuan Wen; Jiao Li; Lina Xu; Shuzhou Chu; Weiyuan Wang; Lei Shi; Guiyuan Xie; Donghai Huang; Songqing Fan
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

Review 4.  The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer.

Authors:  Subhankar Chakraborty; Sukhwinder Kaur; Sushovan Guha; Surinder K Batra
Journal:  Biochim Biophys Acta       Date:  2012-03-31

5.  miR-106a* inhibits the proliferation of renal carcinoma cells by targeting IRS-2.

Authors:  Yadong Ma; Hongyi Zhang; Xiaolong He; Hongxiong Song; Yayong Qiang; Yi Li; Jixue Gao; Ziming Wang
Journal:  Tumour Biol       Date:  2015-05-28

6.  Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type.

Authors:  Amy J VanMeter; Adrianna S Rodriguez; Elise D Bowman; Jin Jen; Curtis C Harris; Jianghong Deng; Valerie S Calvert; Alessandra Silvestri; Claudia Fredolini; Vikas Chandhoke; Emanuel F Petricoin; Lance A Liotta; Virginia Espina
Journal:  Mol Cell Proteomics       Date:  2008-08-06       Impact factor: 5.911

7.  MiR-23a-mediated migration/invasion is rescued by its target, IRS-1, in non-small cell lung cancer cells.

Authors:  Mengru Cao; Yulian Li; Hailing Lu; Qingwei Meng; Long Wang; Li Cai; Xiaoqun Dong
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-05       Impact factor: 4.553

8.  Oncogenic activity of insulin in the development of non-small cell lung carcinoma.

Authors:  Jie Jiang; Hong-Yue Ren; Guo-Jun Geng; Yan-Jun Mi; Yu Liu; Ning Li; Shu-Yu Yang; Dong-Yan Shen
Journal:  Oncol Lett       Date:  2017-11-03       Impact factor: 2.967

9.  Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth.

Authors:  A McGarry Houghton; Danuta M Rzymkiewicz; Hongbin Ji; Alyssa D Gregory; Eduardo E Egea; Heather E Metz; Donna B Stolz; Stephanie R Land; Luiz A Marconcini; Corrine R Kliment; Kimberly M Jenkins; Keith A Beaulieu; Majd Mouded; Stuart J Frank; Kwok K Wong; Steven D Shapiro
Journal:  Nat Med       Date:  2010-01-17       Impact factor: 53.440

10.  Expression and function of the insulin receptor substrate proteins in cancer.

Authors:  Katerina Mardilovich; Shannon L Pankratz; Leslie M Shaw
Journal:  Cell Commun Signal       Date:  2009-06-17       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.